Carrier detection of Hunter syndrome (MPS II) by biochemical and DNA techniques in families at risk.
DNA based and biochemical diagnosis of MPS II was performed on 13 unrelated families using Southern blotting. The 35S-sulphate accumulation in cultured fibroblasts was investigated and the iduronate-2-sulphatase (IDS) activity in the serum determined. Sixteen patients and 36 females at risk were screened for structural aberrations and by RFLP analysis using the intragenic probe pc2S15 and probes VK23B, VK21A, and II-10 for the flanking loci DXS297, DXS296, and DXS466. Structural alterations were found in the DNA of two patients. One of them showed a major deletion including the whole coding sequence of the IDS gene. An aberrant Southern fragment occurred in the HindIII/pc2S15 blot of the other patient suggesting a new HindIII restriction site by point mutation in an IDS gene intron. Twenty-nine females were confirmed as carriers, and for five women the heterozygous state could be excluded. Prenatal diagnosis can be offered to 27 women if requested.
Schröder
W
W
Institute of Medical Genetics, Ernst-Moritz-Arndt University, Greifswald, Germany.
Petruschka
L
L
Wehnert
M
M
Zschiesche
M
M
Seidlitz
G
G
Hopwood
J J
JJ
Herrmann
F H
FH
D015139:Blotting, Southern; D002478:Cells, Cultured; D002872:Chromosome Deletion; D004247:DNA / Q000032:analysis*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006580:Genetic Carrier Screening / Q000379:methods*; D006801:Humans; D007066:Iduronate Sulfatase / Q000097:blood / Q000235:genetics*; D008297:Male; D016532:Mucopolysaccharidosis II / Q000235:genetics* / Q000378:metabolism; D010375:Pedigree; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D012307:Risk Factors
D004247:DNA; D007066:Iduronate Sulfatase